Equities researchers at JPMorgan Chase & Co. initiated coverage on shares of Maze Therapeutics (NASDAQ:MAZE – Get Free Report) in a report released on Tuesday,Benzinga reports. The firm set an “overweight” rating and a $30.00 price target on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 177.26% from the stock’s current price.
Separately, Leerink Partners started coverage on Maze Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $28.00 target price on the stock.
Read Our Latest Research Report on MAZE
Maze Therapeutics Trading Down 10.5 %
About Maze Therapeutics
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Read More
- Five stocks we like better than Maze Therapeutics
- What is a Stock Market Index and How Do You Use Them?
- Confluent: How Data Streaming May Transform AI
- Dividend Capture Strategy: What You Need to Know
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- 3 Warren Buffett Stocks to Buy Now
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
